Summary
Introduction
There is substantial evidence that breast cancer tissue contains all the enzymes responsible for the local biosynthesis of estrogens from circulating precursors. The cytochrome P-450 aromatase enzyme complex is responsible for the conversion of C19 androgens to estrogens and 17-β-hydroxysteroid dehydrogenase (17-β-HSD) type 1 catalyses the inter-conversion of estrone to the biologically more potent estradiol. The gene encoding for the cytochrome P-450 aromatase is known as CYP19 (15q21.2). It is well established that increased exposure to local estrogens is an important risk factor in the genesis and growth of breast cancer. The aim of this study is to investigate the relationship between CYP19 and 17-β-HSD type 1 mRNA expression and clinico-pathological parameters of human breast cancer.
Methods
One hundred and twenty seven tumor tissues and 33 normal tissues were analyzed. The levels of transcription of CYP19 and 17-β-HSD type 1 were determined using real-time quantitative PCR. The mRNA expression was normalized against CK19. Levels of expression were analyzed against tumorâ’s stage, grade, nodal status, local relapse, distant metastasis and survival over a 120 months follow up period. In addition, the levels were analyzed against estrogen receptor (ER) and HER1-4 status.
Results
Overall, high tumor levels of mRNA expression of CYP19 and 17-β-HSD type 1 correlated with poor survival (p=0.0105 and p=0.0182, respectively). Increased levels of CYP19 mRNA expression positively correlated with disease progression as levels were significantly higher in samples of patients who had distant metastasis and local recurrence and/or died of breast related causes when compared to those who were disease free for >10 years (p=0.0015). We also observed higher levels of CYP19 mRNA in tumor samples compared to normal breast tissue. However, this reached statistical significance only when comparing grade 1 tumors with normal tissue (p=0.01). There was no correlation between CYP19á mRNA expression and tumor stage, lymph node status and tumor grade. There was however a trend for a positive correlation between CYP19 and ER mRNA expressions (p=0.06). No significant difference in 17-β-HSD type 1 expression between normal and cancerous tissues was observed. In tumor samples, we observed an increase in levels correlating with tumorâ’s grade. This correlation was statistically significant when we compared grade 1 with grade 2 and grade 1 with grade3 (p=0.0031 and 0.0251, respectively).
Conclusion
Our study shows that higher levels of the enzymes responsible for the local biosynthesis of estrogens especially aromatase are associated with a poor clinical outcome in patients with breast cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Chen S, 1998 Aromatase and breast cancer Front Biosci 3:922â–933
Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. 2005 Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells Steroids 70:372â–381
Garvin S, Nilsson UW, Dabrosin C, 2005 Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells Br J Cancer 93:1005â–1010
Redeuilh G, Attia A, Mester J, Sabbah M 2002 Transcriptional activation by the oestrogen receptor alpha is modulated through inhibition of cyclin-dependent kinases Oncogene 21:5773â–5782
Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ. 1998 In situ aromatization enhances breast tumor estradiol levels and cellular proliferationCancer Res 58:927â–932
Simpson E, Rubin G, Clyne C, Robertson K, Oâ’Donnell L, Davis S, Jones M. 1999 Local estrogen biosynthesis in males and females Endocr Relat Cancer 2:131â–137
Pasqualini JR, Chetrite GS. 2005 Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer J Steroid Biochem Mol Biol 93:221â–236
Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. 2005 Steroid sulfatase: molecular biology, regulation, and inhibition Endocr Rev 2:171â–202
Bulun SE, Simpson ER. 1994 Regulation of aromatase expression in human tissues Breast Cancer Res Treat 30:19â–29
Pasqualini JR. 2004 The selective estrogen enzyme modulators in breast cancer: a review Biochim Biophys Acta 1654:123â–143
Pasqualini JR., Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C. 1996 Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients J Clin Endocr Metab 81:1460â–1464
Santner SJ, Chen S, Zhou D, Korsunsky Z, Martel J, Santen RJ. 1993 Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture J Steroid Biochem Mol Biol 44:611â–616
Reed MJ, 1994 The role of aromatase in breast tumors Breast Cancer Res Treat 30:7â–17
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996 P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature Pharmacogenetics 6:1â–42
Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ, Mendelson CR. 1993 Tissue specific promoters regulate aromatase cytochrome P450 expression J Steroid Biochem Mol Biol 44:321â–330
Simpson ER, Davis SR. 2001 Minireview: aromatase and the regulation of estrogen biosynthesis â– some new perspectivesEndocrinology 142:4589â–4594
Sebastian S, Bulun SE. 2001 A highly complex organization of the regulatory region of the human CYP 19 (Aromatase) gene revealed by the Human Genome Project J Clin Endocrinol Metab 86:4600â–4602
Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulun SE, Zhao Y, 1997 Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage FASEB J 11:29â–36
Harada N, Utsumi T, Takagi Y 1993 Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesisProc Natl Acad Sci USA 90:11312â–11316
Poutanen M, Isomaa V, Lehto VP, Vihko R, 1992 Immunological analysis of 17-β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue Int J Cancer 50:386â–390
Isomaa VV, Ghersevich SA, Maentausta OK, Peotoketo EH, Poutanen MH, Vihko RK 1993 Steroid biosynthetic enzymes: 17-β-hydroxysteroid dehydrogenase Ann Med 25:91â–97
Gunnarsson C, Ahnstrom M, Kirschner K, Olsson B, Nordenskjold B, Rutqvist LE, Skoog L, Stal O. 2003 Amplification of HSD17B1 and ERBB2 in primary breast cancer Oncogene 22:34â–40
Lipton A, Santen RJ, Sanmer SJ, Harvey HA, Sanders SI, Matthews YL 1992 Prognostic value of breast cancer aromatase Cancer 70:1951â–1955
Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL 2000 Genetic variants of CYP19 (aromatase) and breast cancer risk Oncogene 19:1329â–1333
Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Wu X, Kobayashi S, Iwase H. 2003 Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast Breast Cancer Res 5:250â–256
Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K, Harada N 1999 Steroid sulfatase expression is an independent predictor of recurrence in human breast cancerCancer Res 59:377â–381
Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H 2000 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters Br J Cancer 82:518â–523
Jiang WG, Douglas-Jones A, Mansel RE 2003 Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer Int J Cancer 106:752â–757
Jiang WG, Watkins G, Lane J, Douglas-Jones A, Cunnick GH, Mokbel M, Mansel RE. 2003 Prognostic value of Rho family and rho-GDIs in breast cancer Clin Cancer Res 9:6432â–6440
Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE. 2004 Differential expression of the CCN family members Cyr61 from CTGF and Nov in human breast cancer Endocr Relat Cancer 11:781â–791
Yoshimura N, Harada N, Bukholm I, Karesen R, Borresen-Dale AL, Kristensen VN. 2004 Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer Breast Cancer Res 6:46â–55
Yamamoto T, Kitawaki J, Urabe M, Honjo H, Tamra T, Noguchi T, Okada H, Sasaki H, Tada A, Terashima Y, Nakamura J, Yoshihama M. 1993 Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells J Steroid Biochem Mol Biol 44:463â–468
Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y, Noguchi S. 2003 High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer Clin Cancer Res 9:2288â–2293
Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M, Sasano H. 2003 Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma Cancer Res63:2762â–2770
Simpson ER. 2003 Sources of estrogen and their importance J Steroid Biochem Mol Biol 86:225â–230
Nelson LR, Bulun SE. 2001 Estrogen production and action J Am Acad Dermatol 45:116â–124
Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription J Clin Endocrinol Metab 77:1622â–1628
Utsumi T, Harada N, Maruta M, Takagi Y 1996 Presence of alternatively spliced transcripts of aromatase gene in human breast cancer J Clin Endocrinol Metab 81:2344â–2349
James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ 1987 Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies Steroids 50:269â–279
Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM, Telford J. 1997 Regulation of aromatase activity within the breast J Steroid Biochem Mol Biol 61:193â–202
Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA, James VHT. 1989 In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione Int J Cancer 44:233â–237
Zhou D, Pompon D, Chen S. 1990 Stable expression of human aromatase cDNA in mammalian cells â– a useful system for aromatase inhibitor screening Cancer Res 50:6949â–6954
Yue W, Zhou D, Chen S, Brodie A. 1994 A new nude mouse model for post.menopausal breast cancer using MCF-7 cells transfected with the htmmn aromatase gene Cancer Res 54:5092â–5095
Macaulay VM, Nicholl JE, Gledhi UJ, Rowlands MG, Dowsett M, Ashwoa A. 1994 Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer ceils Br J Cancer 69:77â–83
Lee K, Macaulay VM, Nicholls JE, Detre S, Ashworth A, Dowsett M. 1995 An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells Int J Cancer 62:297â–302
Miller WR, Anderson TJ, Lack WJL. 1990 Relationship between tumor aromatase activity, tumor characteristics and response to therapy, fr. Steroid Biochem Mol Biol 37:1055â–1059
Zhang Z, Yamashita H, Toyama T, Hara Y, Omoto Y, Sugiura H, Kobayashi S, Harada N, Iwase H 2002 Semi quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast Breast Cancer Res Treat 74:47â–53
Sasano H, Nagura H, Harada N, Goukon Y, Kimyra M. 1994 Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders Hum Pathol 25:530â–535
Brodie A, Lu Q, Nakamura J 1997 Aromatase in the normal breast and breast cancer J Steroid Biochem Mol Biol 61:281â–286
Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A 1996 Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers Endocrinology 137:3061â–3068
Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Buhm SE, Silverberg SG, Nagura H 1996 Aromatase and 17-β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma J Clin Endocrinol Metab 11:4042â–4046
Gunnarsson C, Olsson BM, Stal O 2001 Southeast Sweden Breast Cancer Group Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence Cancer Res 61:8448â–8451
Feigelson SH, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE 2001 Building a multigenic model of breast cancer susceptibility: CYP 17 and HSD 17β1 are two important candidates Cancer Res 61:785â–789
Sourdaine P, Mullen P, White R, Telford J, Parker MG, Miller WR. 1996 Aromatase activity and CYP19 gene expression in breast cancers J Steroid Biochem Mol Biol 59:191â–198
Santner SJ, Pauley RJ, Tait L, Kaseta J, Santen RJ 1997 Aromatase activity and expression in breast cancer and benign breast tissue stromal cells J Clin Endocrinol Metab 82:200â–208
The ATAC (Arimidex Tamoxifen alone or in Combination) Trialistsâ’ Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131â–2139
Cunnick GH, Mokbel K. 2001 Aromatase inhibitors Curr Med Res Opin 17:217â–222
Mokbel K. 2002 The evolving role of aromatase inhibitors in breast cancer Int J Clin Oncol 7:279â–283
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salhab, M., Reed, M., Al Sarakbi, W. et al. The role of aromatase and 17-β-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res Treat 99, 155–162 (2006). https://doi.org/10.1007/s10549-006-9198-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9198-8